<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; UCPMP</title>
	<atom:link href="http://www.tapanray.in/tag/ucpmp/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>India’s Healthcare Is Still Not Patient-Friendly &#8211; Why ‘Patient Centricity’ in Pharma Remains a Slogan More Than a System</title>
		<link>http://www.tapanray.in/indias-healthcare-is-still-not-patient-friendly-why-patient-centricity-in-pharma-remains-a-slogan-more-than-a-system/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-healthcare-is-still-not-patient-friendly-why-patient-centricity-in-pharma-remains-a-slogan-more-than-a-system</link>
		<comments>http://www.tapanray.in/indias-healthcare-is-still-not-patient-friendly-why-patient-centricity-in-pharma-remains-a-slogan-more-than-a-system/#comments</comments>
		<pubDate>Sun, 23 Nov 2025 14:17:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[friendly]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hospitals]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[not patient]]></category>
		<category><![CDATA[Patient-Centricity]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[slogan]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=11004</guid>
		<description><![CDATA[Executive Summary: Despite constant advocacy around “patient centricity,” India’s healthcare ecosystem &#8211; from pharma to hospitals &#8211; continues to show deep structural gaps. Safety failures, unethical marketing practices, opaque pricing, and hospital-level exploitation still undermine patient trust. This article uses illustrative &#8230; <a href="http://www.tapanray.in/indias-healthcare-is-still-not-patient-friendly-why-patient-centricity-in-pharma-remains-a-slogan-more-than-a-system/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-healthcare-is-still-not-patient-friendly-why-patient-centricity-in-pharma-remains-a-slogan-more-than-a-system/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pills and Payments: India&#8217;s Unethical Drug Marketing Problem</title>
		<link>http://www.tapanray.in/pills-and-payments-indias-unethical-drug-marketing-problem/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pills-and-payments-indias-unethical-drug-marketing-problem</link>
		<comments>http://www.tapanray.in/pills-and-payments-indias-unethical-drug-marketing-problem/#comments</comments>
		<pubDate>Fri, 27 Jun 2025 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[payments]]></category>
		<category><![CDATA[pills]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[unethical]]></category>
		<category><![CDATA[Vikshit]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10925</guid>
		<description><![CDATA[The recent exposé by The Economic Times, titled &#8220;Rx Name Unethical practitioners,&#8221; published on June 19, 2025, which brought to light allegations of a prominent global pharmaceutical company sponsoring extravagant foreign trips for doctors in violation of ethical codes, serves as &#8230; <a href="http://www.tapanray.in/pills-and-payments-indias-unethical-drug-marketing-problem/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pills-and-payments-indias-unethical-drug-marketing-problem/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>UCPMP: Vacillating Between ‘The Perfect’ And ‘The Real’ World?</title>
		<link>http://www.tapanray.in/ucpmp-vacillating-between-the-perfect-and-the-real-world/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ucpmp-vacillating-between-the-perfect-and-the-real-world</link>
		<comments>http://www.tapanray.in/ucpmp-vacillating-between-the-perfect-and-the-real-world/#comments</comments>
		<pubDate>Mon, 02 Mar 2020 00:00:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Association]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[Uniform]]></category>
		<category><![CDATA[Vacillating]]></category>
		<category><![CDATA[Voluntary]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[‘The Perfect’]]></category>
		<category><![CDATA[‘The Real’]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9896</guid>
		<description><![CDATA[In the ‘perfect world’ one takes ‘perfect decisions’, while in the ‘real world’ one takes a ‘real decision’ &#8211; as the saying goes. In tandem, a raging debate continues on what is ‘perfect’ and what is ‘real’, in the world &#8230; <a href="http://www.tapanray.in/ucpmp-vacillating-between-the-perfect-and-the-real-world/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/ucpmp-vacillating-between-the-perfect-and-the-real-world/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Quality Imbroglio And ‘Culture of Bending Rules’ in India</title>
		<link>http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-quality-imbroglio-and-culture-of-bending-rules-in-india</link>
		<comments>http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/#comments</comments>
		<pubDate>Mon, 27 May 2019 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bending]]></category>
		<category><![CDATA[bias]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[culpable]]></category>
		<category><![CDATA[culture]]></category>
		<category><![CDATA[Culture of Bending Rules]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[dubious]]></category>
		<category><![CDATA[Facts]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[letter]]></category>
		<category><![CDATA[margin]]></category>
		<category><![CDATA[multinational]]></category>
		<category><![CDATA[negative]]></category>
		<category><![CDATA[non-branded]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[quagmire]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[questionable]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[rules]]></category>
		<category><![CDATA[specific]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[US-FDA]]></category>
		<category><![CDATA[warning]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9539</guid>
		<description><![CDATA[“Bottle Of Lies Exposes The Dark Side Of The Generic-Drug Boom” &#8211; re-emphasized the book, released in May 2019.  This confirms, the raging debate on the questionable quality of many generic drugs manufactured in India and involving several top domestic pharma companies, &#8230; <a href="http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Are Cancer Patients Victims of Pharma’s Payment to Doctors &#8211; For Prescriptions?</title>
		<link>http://www.tapanray.in/are-cancer-patients-victims-of-pharmas-payment-to-doctors-for-prescriptions/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=are-cancer-patients-victims-of-pharmas-payment-to-doctors-for-prescriptions</link>
		<comments>http://www.tapanray.in/are-cancer-patients-victims-of-pharmas-payment-to-doctors-for-prescriptions/#comments</comments>
		<pubDate>Mon, 04 Mar 2019 00:00:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Catering]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Evaluation]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pay]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Prescribing]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[relatioship]]></category>
		<category><![CDATA[Sloan]]></category>
		<category><![CDATA[UCPMP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9432</guid>
		<description><![CDATA[In pharma industry, people of all socioeconomic backgrounds have no other choice but to visit doctors, to seek their expert advice for medical treatment. Patients expect them to prescribe the right and most affordable medicines for desired relief. Ironically, it &#8230; <a href="http://www.tapanray.in/are-cancer-patients-victims-of-pharmas-payment-to-doctors-for-prescriptions/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/are-cancer-patients-victims-of-pharmas-payment-to-doctors-for-prescriptions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Uniting Pharma With Business Ethics: A Bridge Too Far?</title>
		<link>http://www.tapanray.in/uniting-pharma-with-business-ethics-a-bridge-too-far/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=uniting-pharma-with-business-ethics-a-bridge-too-far</link>
		<comments>http://www.tapanray.in/uniting-pharma-with-business-ethics-a-bridge-too-far/#comments</comments>
		<pubDate>Mon, 18 Feb 2019 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AIDS]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[bridge]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[far]]></category>
		<category><![CDATA[gift]]></category>
		<category><![CDATA[IFPMA]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[operations]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[promotional]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reminders]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[uniting]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9414</guid>
		<description><![CDATA[Operating ethically not only is the right thing to do but also is fundamental to success in business. Poor governance and poor ethical business practices can lead to fines, public scrutiny and distrust – overshadowing good performance, destroying reputation, and &#8230; <a href="http://www.tapanray.in/uniting-pharma-with-business-ethics-a-bridge-too-far/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/uniting-pharma-with-business-ethics-a-bridge-too-far/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patients’ Trust And Pharma Remain Strange Bedfellows?</title>
		<link>http://www.tapanray.in/patients-trust-and-pharma-remain-strange-bedfellows/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patients-trust-and-pharma-remain-strange-bedfellows</link>
		<comments>http://www.tapanray.in/patients-trust-and-pharma-remain-strange-bedfellows/#comments</comments>
		<pubDate>Mon, 03 Sep 2018 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bedfellows]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Council]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[gap]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relationship]]></category>
		<category><![CDATA[strange]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trust]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[uneasy]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9129</guid>
		<description><![CDATA[Like many other industries, pharmaceutical companies too often talk about improving focus on effective ‘stakeholder-relationship management’. The doctors obviously form an integral part of this process. There is nothing wrong with it. Nevertheless, serious concern of ‘conflict of interest’ between &#8230; <a href="http://www.tapanray.in/patients-trust-and-pharma-remain-strange-bedfellows/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patients-trust-and-pharma-remain-strange-bedfellows/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Should ‘Pharma Marketing’ Be In The Line of Fire?</title>
		<link>http://www.tapanray.in/should-pharma-marketing-be-in-the-line-of-fire/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=should-pharma-marketing-be-in-the-line-of-fire</link>
		<comments>http://www.tapanray.in/should-pharma-marketing-be-in-the-line-of-fire/#comments</comments>
		<pubDate>Sun, 26 Nov 2017 23:31:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA['condo']]></category>
		<category><![CDATA[ails]]></category>
		<category><![CDATA[Allegation]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[decision]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[fire]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intrinsic]]></category>
		<category><![CDATA[line]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[medication]]></category>
		<category><![CDATA[OTC]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[serious]]></category>
		<category><![CDATA[support]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8570</guid>
		<description><![CDATA[Close to half a century ago, Peter Drucker &#8211; the Management Guru wrote: As the purpose of business is to create customers, any business enterprise has two basic functions: marketing and innovation. Drucker’s concept is so fundamental in nature that it will possibly never change, ever. That innovation &#8230; <a href="http://www.tapanray.in/should-pharma-marketing-be-in-the-line-of-fire/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/should-pharma-marketing-be-in-the-line-of-fire/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Marketing Practices: Why Pharma Does What It Does?</title>
		<link>http://www.tapanray.in/marketing-practices-why-pharma-does-what-it-does/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=marketing-practices-why-pharma-does-what-it-does</link>
		<comments>http://www.tapanray.in/marketing-practices-why-pharma-does-what-it-does/#comments</comments>
		<pubDate>Mon, 11 Sep 2017 00:00:43 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[Allergan]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[Brent]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[CME]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Jimenez]]></category>
		<category><![CDATA[Joe]]></category>
		<category><![CDATA[Joseph]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[pharma. policy]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[proposals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Saunders]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8408</guid>
		<description><![CDATA[It started way back &#8211; spanning across many developed countries of the world. However, probably for the first time in the last five years, an international media group focused on this issue thriving in India, with so much detail. Reuters &#8230; <a href="http://www.tapanray.in/marketing-practices-why-pharma-does-what-it-does/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/marketing-practices-why-pharma-does-what-it-does/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Draft Pharma Policy 2017 Ticks The Right Boxes: A Challenge Still Remains</title>
		<link>http://www.tapanray.in/draft-pharma-policy-2017-ticks-the-right-boxes-a-challenge-still-remains/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=draft-pharma-policy-2017-ticks-the-right-boxes-a-challenge-still-remains</link>
		<comments>http://www.tapanray.in/draft-pharma-policy-2017-ticks-the-right-boxes-a-challenge-still-remains/#comments</comments>
		<pubDate>Mon, 04 Sep 2017 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[Bank]]></category>
		<category><![CDATA[Boxes]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[GLP]]></category>
		<category><![CDATA[GMP]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[ticks]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8396</guid>
		<description><![CDATA[Pharma policy is not a panacea to address all related issues, neither for the patients nor the industry, in general. As I see it, it’s no more than a critical cog in the wheel of the overall macro and the &#8230; <a href="http://www.tapanray.in/draft-pharma-policy-2017-ticks-the-right-boxes-a-challenge-still-remains/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/draft-pharma-policy-2017-ticks-the-right-boxes-a-challenge-still-remains/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
